WAVE LIFE SCIENCES LTD

NASDAQ: WVE (Wave Life Sciences Ltd.)

最近更新时间: 01 Dec, 6:30PM

15.10

0.11 (0.73%)

前收盘价格 14.99
收盘价格 14.89
成交量 623,952
平均成交量 (3个月) 1,879,433
市值 2,303,052,032
价格/销量 (P/S) 30.89
股市价格/股市净资产 (P/B) 14.20
52周波幅
3.50 (-76%) — 16.74 (10%)
利润日期 12 Nov 2024
营业毛利率 -265.84%
营业利益率 (TTM) 832.66%
稀释每股收益 (EPS TTM) -1.12
季度收入增长率 (YOY) -10.90%
总债务/股东权益 (D/E MRQ) 18.17%
流动比率 (MRQ) 1.90
营业现金流 (OCF TTM) -140.62 M
杠杆自由现金流 (LFCF TTM) -7.89 M
资产报酬率 (ROA TTM) -34.04%
股东权益报酬率 (ROE TTM) -243.82%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Wave Life Sciences Ltd. 看涨 看涨

AIStockmoo 评分

-1.0
分析师共识 1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 -0.5
平均 -1.00

相关股票

股票 市值 DY P/E(TTM) P/B
WVE 2 B - - 14.20
ARGX 37 B - - 8.52
ALNY 32 B - - 972.68
ROIV 9 B - 2.17 1.63
INCY 13 B - 771.11 4.19
SMMT 13 B - - 28.58

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Growth
内部持股比例 15.04%
机构持股比例 78.72%
52周波幅
3.50 (-76%) — 16.74 (10%)
目标价格波幅
15.00 (-0%) — 36.00 (138%)
36.00 (Truist Securities, 138.41%) 购买
22.00 (45.70%)
15.00 (RBC Capital, -0.66%) 保留
平均值 21.60 (43.05%)
总计 9 购买, 1 保留
平均价格@调整类型 14.32
公司 日期 目标价格 调整类型 价格@调整类型
Mizuho 21 Nov 2024 22.00 (45.70%) 购买 14.35
HC Wainwright & Co. 13 Nov 2024 22.00 (45.70%) 购买 15.69
31 Oct 2024 22.00 (45.70%) 购买 13.71
Truist Securities 12 Nov 2024 36.00 (138.41%) 购买 15.89
B. Riley Securities 04 Nov 2024 22.00 (45.70%) 购买 13.79
03 Oct 2024 19.00 (25.83%) 购买 8.50
RBC Capital 21 Oct 2024 15.00 (-0.66%) 保留 15.11
04 Oct 2024 7.00 (-53.64%) 保留 8.41
JP Morgan 17 Oct 2024 17.00 (12.58%) 购买 14.61
27 Sep 2024 13.00 (-13.91%) 购买 8.29
Leerink Partners 16 Oct 2024 22.00 (45.70%) 购买 14.90
Raymond James 16 Oct 2024 22.00 (45.70%) 购买 14.90
Wells Fargo 16 Oct 2024 22.00 (45.70%) 购买 14.90
Jones Trading 25 Sep 2024 16.00 (5.96%) 购买 9.01
显示更多

该时间范围内无数据。

日期 类型 细节
16 Dec 2024 公告 Wave Life Sciences to Present at 43rd Annual J.P. Morgan Healthcare Conference
26 Nov 2024 公告 Wave Life Sciences to Present at Upcoming Investor Conferences
15 Nov 2024 公告 Wave Life Sciences to Present at Jefferies London Healthcare Conference
12 Nov 2024 公告 Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
04 Nov 2024 公告 Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024
30 Oct 2024 公告 Wave Life Sciences Highlights Growing Pipeline at Research Day, including INHBE siRNA Program for Obesity and New RNA Editing Programs
16 Oct 2024 公告 Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency
16 Oct 2024 公告 Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024
01 Oct 2024 公告 Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares 
30 Sep 2024 公告 Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference
25 Sep 2024 公告 Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
24 Sep 2024 公告 Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping
24 Sep 2024 公告 Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2024 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票